Lancet
-
Randomized Controlled Trial Multicenter Study Comparative Study Clinical Trial
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.
In patients with heart failure, beta-blockade has improved morbidity and left-ventricular function, but the impact on survival is uncertain. We investigated the efficacy of bisoprolol, a beta1 selective adrenoceptor blocker in decreasing all-cause mortality in chronic heart failure. ⋯ Beta-blocker therapy had benefits for survival in stable heart-failure patients. Results should not, however, be extrapolated to patients with severe class IV symptoms and recent instability because safety and efficacy has not been established in these patients.